NPCE reports today with the Street broadly constructive but key questions about profitability still unanswered.
Options positioning has tilted more defensive in the run-up to the print. The put/call ratio climbed to 0.78, well above its 20-day average of 0.54 — about 1.2 standard deviations elevated — suggesting investors have been adding more downside protection than usual heading into today's release. That caution follows a rough month for the stock: NPCE is down roughly 12% over the past 30 days to $15.05, though it has clawed back around 6% over the past week. The borrow market tells a different story — availability is extremely loose at 1,860%, meaning shares to borrow are plentiful relative to what is already shorted. Short interest itself is modest at 2.4% of the free float and has been declining over the past week, down nearly 4%. There is no meaningful squeeze pressure here.
The analyst community has been warming to the story ahead of the print. Mizuho initiated coverage in late July with an Outperform rating and a $22 target, the freshest external endorsement in the build-up. HC Wainwright reiterated its Buy and $20 target days later. The consensus across eight covering analysts lands at Buy, with a mean target of $20.22 — implying roughly 34% upside from current levels. Bulls point to NeuroPace's RNS system delivering a clinically meaningful 3.2-point improvement in QOLIE-89 quality-of-life scores and a structural tailwind from the rapid expansion of Comprehensive Epilepsy Centers. Bears counter with the company's unbroken string of net losses, no clear timeline to profitability, and an ongoing reliance on external capital that could arrive on unfavorable terms. The EV/EBITDA multiple is deeply negative and the price-to-book ratio runs above 25x — not a value story by any measure.
Institutional ownership is concentrated and active. Accelmed Partners holds 13% of shares and made no change to its position in the most recent filing period, suggesting conviction rather than momentum. First Light Asset Management added over 1.1 million shares through March, a substantial build for a name of this size. On the insider side, CEO Joel Becker and Chief Medical Officer Martha Morrell have both been selling on a regular schedule throughout 2026 — small amounts relative to the company's float, all carrying a trade significance score of just 1, consistent with routine programmatic selling rather than a directional signal on the stock.
Today's print will test whether NeuroPace's revenue trajectory is tracking the growth rates analysts have underwritten — and whether management can offer any concrete markers on the path toward cash-flow breakeven that might justify a valuation built almost entirely on commercial momentum.
See the live data behind this article on ORTEX.
Open NPCE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
